DNA甲基化差异与类风湿关节炎甲氨蝶呤治疗反应相关
研究基于类风湿关节炎用药研究(RAMS)队列,比较甲氨蝶呤治疗前与4周时全血DNA甲基化差异,发现2个CpG位点甲基化变化与6个月时EULAR临床反应相关;12个与关节计数或CRP变化相关的CpG中4个在独立样本中重复验证。
要点
- 4周时2个CpG位点甲基化变化与6个月EULAR反应相关
- 12个CpG与TJC、SJC或CRP变化相关,4个获独立重复
- 提示DNA甲基化或可早期(4周)预测甲氨蝶呤反应
核心结论
- 差异DNA甲基化可作为甲氨蝶呤治疗反应的候选生物标志物,支持个体化治疗策略。
研究设计与样本
- 研究基于类风湿关节炎用药研究(RAMS)队列,发现组比较基线至4周全血DNA甲基化,反应良好与反应差各34例。
- 采用线性模型校正性别、年龄、细胞组成、基线DAS28和吸烟状态。
- 在RAMS独立组100例患者中用焦磷酸测序验证。
主要发现
- 发现组中2个CpG位点4周时甲基化变化与6个月EULAR临床反应相关。
- 3个差异甲基化位点变化与压痛关节数变化相关,3个与肿胀关节数变化相关,另4个与CRP变化相关。
- 12个CpG中4个在RAMS独立数据集中重复验证到关联。
关键数值与推荐
- 发现组反应良好34例、反应差34例;验证组100例。
- 比较时间点为基线至4周,结局为6个月EULAR反应及DAS28、SJC、TJC、CRP变化。
临床怎么用
- 甲氨蝶呤治疗4周时检测DNA甲基化变化,可能辅助早期判断6个月临床反应。
- 若验证成熟,可支持在4周时升级或更换治疗方案。
局限性
- 发现组样本量较小(各34例),验证仅4个CpG重复。
- 研究为观察性队列,需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Identifying blood-based biomarkers that predict treatment response in RA is a clinical priority. We investigated differential DNA methylation as a candidate biomarker of response for the first-line drug used in RA, MTX. METHODS: DNA methylation was measured in DNA samples from individuals recruited to the Rheumatoid Arthritis Medication Study. Differentially methylated positions were compared between whole blood samples collected at baseline and at 4 weeks from patients who, by 6 months, had a good (n = 34) or poor response (n = 34) to MTX using linear modelling, adjusting for gender, age, cell composition, baseline 28-joint disease activity score (DAS28) and smoking status. Analyses also compared methylation with changes in DAS28 and changes in swollen joint count and tender joint count, and changes in CRP over the initial 6 months after MTX commencement. Differentially methylated positions showing significant differences with any response parameter were tested using pyrosequencing in an independent group of 100 patients from the Rheumatoid Arthritis Medication Study. RESULTS: In the discovery group, two CpG sites showed methylation changes at 4 weeks associated with clinical EULAR response by 6 months. Significant changes in methylation for three differentially methylated positions associated with change in tender joint counts, three with change in swollen joint count and a further four with change in CRP. Of the 12 CpGs, four showed replicated association in an independent dataset of samples from the Rheumatoid Arthritis Medication Study. CONCLUSION: These data represent an advance on current practice by contributing to a personalized medicine strategy allowing an escalation or change in therapy as early as 4 weeks.
引用
- Nair N, Plant D, Verstappen SM, et al. Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 31598719. doi:10.1093/rheumatology/kez411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。